NCT05237713 - Efficacy and Safety of Canakinumab for the Treatment of Anemia in LR-MDS Patients | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

April 26, 2022

Primary Completion Date

February 29, 2024

Study Completion Date

February 29, 2024

Conditions

AnemiaMyelodysplastic Syndromes

Interventions

DRUG

Canakinumab Injection

Administration for a duration of 6 months for all patients and in case of response further treatment for up to three years

Trial Locations (3)

"Medizinisches Versorgungszentrum Onkologischer Schwerpunkt am Oskar- Helene-Heim", Berlin

Universitätsklinikum Carl Gustav Carus an der Technischen Universität Dresden Medizinischen Klinik und Poliklinik I / Hämatologie, Dresden

Klinik und Poliklinik für Hämatologie und Zelltherapie, Hämostaseologie, Leipzig